Guanosine-specific cyclic nucleotide signaling is suggested to serve protective actions in the vasculature; however, the influence of selective pharmacologic modulation of cyclic guanosine monophosphate— synthesizing soluble guanylate cyclase or cyclic guanosine monophosphate—degrading phosphodiesterase on vessel remodeling has not been thoroughly examined. In this study, rat carotid artery balloon injury was performed and the growth-modulating effects of the soluble guanylate cyclase stimulator YC-1 or the cyclic guanosine monophosphate—dependent phosphodiesterase-V inhibitor zaprinast were examined. YC-1 or zaprinast elevated vessel cyclic guanosine monophosphate content, reduced medial wall and neointimal cell proliferation, stimulated medial and neointimal cellular apoptosis, and markedly attenuated neointimal remodeling in comparable fashion. Interestingly, soluble guanylate cyclase inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one failed to noticeably alter neointimal growth, and concomitant zaprinast with YC-1 did not modify any parameter compared to individual treatments. These results provide novel in vivo evidence that YC-1 and zaprinast inhibit injury-induced vascular remodeling through antimitogenic and proapoptotic actions and may offer promising therapeutic approaches against vasoproliferative disorders.
Tulis DA, Durante W., Liu XM, Evans AJ, Peyton KJ, Schafer AIAdenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation. 2001;104:2710-2715.
2.
Tulis DA, Durante W., Peyton KJ, Evans AJ, Schafer AIHeme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. Atherosclerosis. 2001 ;155:113-122.
3.
Tulis DA, Keswani AN, Peyton KJ, Wang H., Schafer AI, Durante W.Local administration of carbon monoxide inhibits neointima formation in balloon injured rat carotid arteries. Cell Mol Biol. 2005;51:441-446.
4.
Ko FN, Wu CC, Kuo SC, Lee FY, Teng CMYC-1, a novel activator of platelet guanylate cyclase. Blood . 1994;84: 4226-4233.
5.
Wu CC, Ko FN, Kuo SC, Lee FY, Teng CMYC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol. 1995;116:1973-1978.
6.
Tulis DA, Durante W., Peyton KJ, Chapman GB, Evans AJ, Schafer AIYC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem Biophys Res Commun. 2000;279: 646-652.
7.
Tulis DA, Bohl Masters KS, Lipke EA, et al. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. Biochem Biophys Res Commun. 2002;291:1014-1021.
8.
Wu CH, Chang WC, Chang GY, Kuo SC, Teng CMThe inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. J Pharmacol Sci. 2004;94:252-260.
9.
Tulis DASalutary properties of YC-1 in the cardiovascular and hematological systems . Curr Med Chem Cardiovasc Hematol Agents. 2004;2:343-359.
10.
Liu YC, Pan SL, Peng CY, et al. YC-1 [3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J Pharmacol Exp Ther. 2006;316: 35-41.
11.
Tulis DANovel therapies for cyclic GMP control of vascular smooth muscle growth . Am J Ther. 2008;15: 551-564.
12.
Stowe F., Novalija E.Phosphodiesterase type 5 inhibition enhances vasorelaxation caused by nitroprusside in guinea pig intact heart and isolated aorta. J Cardiovasc Pharmacol. 2000;36:162-168.
13.
Kulkarni SK , Patil CSPhosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol. 2004; 26:789-799.
14.
Tsai BM, Wang M., Pitcher JM, Kher A., Crisostomo P., Meldrum DRZaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone. Shock. 2005 ;24:417-420.
15.
Schutte H., Witzenrath M., Mayer K., et al. The PDE inhibitor zaprinast enhances NO-mediated protection against vascular leakage in reperfused lungs. Am J Physiol Lung Cell Mol Physiol. 2000;279:L496-L502.
16.
Vemulapalli S., Chiu PJ, Kurowski S., Brown A., Hartman DB, Leach MWIn vivo inhibition of platelet adhesion by a cGMP-mediated mechanism in balloon catheter injured rat carotid artery. Pharmacology. 1996;52: 235-242.
17.
Indolfi C., Avvedimento EV, Di Lorenzo E., et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med. 1997;3:775-779.
18.
Inoue Y., Toga K., Sudo T., et al. Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model. Br J Pharmacol. 2000;130:231-241.
19.
Kim MJ, Park KG, Lee KM, et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension. 2005;45: 552-556.
Tulis DAHistological and morphometric analyses for rat carotid artery balloon injury studies. Methods Mol Med. 2007;139:31-66.
22.
Abbott RE, Schachter D.Regional differentiation in rat aorta, L-arginine metabolism and cGMP content in vitro. Am J Physiol. 1994;266:H2287-H2295.
23.
Chiang WC, Teng CM, Lin SL, Chen YM, Tsai TJ, Hsieh BSYC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor . Eur J Pharmacol. 2005;517:1-10.
24.
Redondo J., Bishop JE, Wilkins MREffect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol . 1998;124:1455-1462.
25.
Friebe A., Mullershausen F., Smolenski A., Walter U., Schultz G., Koesling D.YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol. 1998;54:962-967.
26.
Galle J., Zabel U., Hubner U., et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol. 1999;127:195-203.
27.
Hwang TL, Zhuo SK, Pan YLYC-1 attenuates homotypic neutrophil aggregation through inhibition of phosphodiesterase activity. Eur J Pharmacol. 2007;579: 395-402.
28.
Hamad AM, Knox AJMechanisms mediating the antiproliferative effects of nitric oxide in cultured human airway smooth muscle cells. FEBS Lett. 2001;506: 91-96.
29.
Cook ALM , Haynes JMProtein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal . 2004;16:253-261.
30.
Zhu B., Strada S., Stevens T.Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol . 2005;289:L196-L206.
Wu CF, Bishopric NH, Pratt REAtrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes . J Biol Chem. 1997;272:14860-14866.
33.
Sarfati M., Mateo V., Baudet S., et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells . Blood. 2003;101:265-269.
34.
Brunetti M. , Mascetra N., Manarini S., et al. Inhibition of cGMP-dependent protein kinases potently decreases neutrophil spontaneous apoptosis . Biochem Biophys Res Commun. 2002;297:498-501.
35.
Ferrero R., Torres M.Prolonged exposure to YC-1 induces apoptosis in adrenomedullary endothelial and chromaffin cells through a cGMP-independent mechanism. Neuropharm. 2001;41:895-906.
36.
Lukowski R. , Weinmeister P., Bernhard D., et al. Role of smooth muscle cGMP/cGKI signaling in murine vascular restenosis. Arterioscler Thromb Vasc Biol . 2008;28: 1244-1250.
